about
What lessons can be learned from γδ T cell-based cancer immunotherapy trials?Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumoursPitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.A functional gammadeltaTCR/CD3 complex distinct from gammadeltaT cells is expressed by human eosinophils.Sorting protein lists with nwCompare: a simple and fast algorithm for n-way comparison of proteomic data files.Hammada scoparia flavonoids and rutin kill adherent and chemoresistant leukemic cells.Metabolic routes as targets for immunological discrimination of host and parasite.Phosphoantigen presentation by macrophages to mycobacterium tuberculosis--reactive Vgamma9Vdelta2+ T cells: modulation by chloroquine.Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes.Science and society: promoting the learning of immunology in developing countries.Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.Influence of stress on extracellular matrix and integrin biology.How tumors might withstand γδ T-cell attack.Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives.Cancer stem cells of differentiated B-cell malignancies: models and consequences.Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.UVA-activated synthesis of metalloproteinases 1, 3 and 9 is prevented by a broad-spectrum sunscreen.Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis.Evidence for early infection of nonneoplastic natural killer cells by Epstein-Barr virus.Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.Rituximab inhibits B-cell receptor signaling.Active trans-synaptic capture of membrane fragments by natural killer cells.Escherichia coli produces phosphoantigens activating human gamma delta T cells.Stimulation of gamma delta T cells by phosphoantigens.B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses.Characterization of phosphoantigens by high-performance anion-exchange chromatography-electrospray ionization ion trap mass spectrometry and nanoelectrospray ionization ion trap mass spectrometry.Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons.Ex vivo development of functional human lymph node and bronchus-associated lymphoid tissue.Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells.Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.Tailored control and optimisation of the number of phosphonic acid termini on phosphorus-containing dendrimers for the ex-vivo activation of human monocytes.FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways.Lipophilic fluorochrome trackers of membrane transfers between immune cells.IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and FcαRI.Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.
P50
Q26849323-BC477DAB-81AD-4C3F-B3B3-ECDA1F07F90FQ28287583-4CD09B02-1921-44FC-8CD3-8B5A1852C14FQ28474331-9ECF6C1C-4AB6-42B2-B6D4-B22A83876728Q33451518-D0AEB904-CE39-4F54-BC87-3AABAF20EB5DQ33470249-74BB3D17-8496-494B-A74A-B0AE2E3E57CBQ33521954-12607E8A-A812-4CEA-9AC3-822EF20344DDQ33788824-C6D4DEC3-75FE-4973-8380-5D010C5443ACQ33971678-0ACCFC4D-92B2-486B-B59D-02A1ABE0FA7BQ34127581-F5F162C7-9BA4-4F93-8C44-9ACABDF73B90Q35896878-CC7D7AE9-C7FF-48FE-BA08-3551977B99B9Q36263018-CD56297A-7885-4DA9-8A93-296DCBDF24B7Q37724953-06E8735E-161C-41DE-B146-BF1D3F38F368Q37845642-82ED1A58-E45A-4574-964F-9E38307FD92FQ37872644-C8786F55-0AAA-47D9-A46C-59370C7A5F86Q37932885-4A70A084-CEB9-4AD4-9D46-EEC68D9F0936Q38161351-C08BA9EE-C76F-459D-944F-F7CAF422A9CCQ39402566-FD0783FC-536A-44AE-8379-4629407BD18CQ39441616-B6C6F763-4A9B-4CF1-B971-636C9EA1A1FAQ39472188-23FAE20A-FCE6-47DF-836C-E35F982D675FQ39685222-10969792-0BD8-444A-88FD-AD3B86E2AD30Q39704505-0F5A310D-09ED-497C-A0A4-D0996050FC8BQ39766389-869A1095-EC04-4E67-AB98-40DB8251CD9BQ40735213-97B873B3-0422-453E-8F04-EB9B83991643Q40772864-C3CE9282-6875-48BF-9A96-B8CBDEDD598FQ41171464-6AAB0B74-C75F-4823-A051-12FCEA698340Q42912844-8DF71A0C-8BA6-470C-A28A-B3DC44ED01DDQ43162657-8E94784E-4B33-43F8-B44A-E010239C0E35Q43279358-6B2443CF-3BEC-4EF5-97AE-8C108A0E8BEFQ43711171-1A3A0B68-4C43-498D-A607-EA39D70AEF3AQ43837795-C84F5B9B-D786-4AF1-9225-C3CF6A72239FQ43918527-35D9D9D1-DCCF-4A0E-B85E-99709ED858B1Q44069892-B4750F4C-5175-45BD-96E1-503E94748982Q44671613-3EDF926D-9404-4DA8-910A-973AE9A2FA58Q45202285-8784FC53-2ECE-4225-9852-D2B950227950Q46131239-008B03BA-F3C9-4AAB-B8C8-CD620978C5DBQ46655287-0F866C3B-4F27-4FC6-849D-8A62828B73DDQ47391978-03982C89-4874-48D2-8982-85430B300AE4Q48892895-C8F4A18D-0F7E-436D-BD23-E3727AECBDC8Q50569444-E857F94F-DAA4-4E6C-A7C5-2ED22E3FAF50Q50996147-C0F5CD35-D7B6-48E1-A086-2E16C89D7A78
P50
description
Frans onderzoeker
@nl
French researcher
@en
chercheur oncologue français à l'INSERM
@fr
hulumtues
@sq
հետազոտող
@hy
name
Jean-Jacques Fournié
@ast
Jean-Jacques Fournié
@cs
Jean-Jacques Fournié
@de
Jean-Jacques Fournié
@en
Jean-Jacques Fournié
@es
Jean-Jacques Fournié
@fr
Jean-Jacques Fournié
@hr
Jean-Jacques Fournié
@nl
Jean-Jacques Fournié
@pl
Jean-Jacques Fournié
@sk
type
label
Jean-Jacques Fournié
@ast
Jean-Jacques Fournié
@cs
Jean-Jacques Fournié
@de
Jean-Jacques Fournié
@en
Jean-Jacques Fournié
@es
Jean-Jacques Fournié
@fr
Jean-Jacques Fournié
@hr
Jean-Jacques Fournié
@nl
Jean-Jacques Fournié
@pl
Jean-Jacques Fournié
@sk
prefLabel
Jean-Jacques Fournié
@ast
Jean-Jacques Fournié
@cs
Jean-Jacques Fournié
@de
Jean-Jacques Fournié
@en
Jean-Jacques Fournié
@es
Jean-Jacques Fournié
@fr
Jean-Jacques Fournié
@hr
Jean-Jacques Fournié
@nl
Jean-Jacques Fournié
@pl
Jean-Jacques Fournié
@sk
P1053
J-7805-2013
P1153
7005651109
P21
P27
P31
P3829
P496
0000-0001-6542-6908